Lundbeck

Lundbeck, Otsuka expand alliance, plan to development Lu AE58054 for Alzheimer's

Wednesday, March 27, 2013 11:24 AM

Global pharmaceutical company H. Lundbeck and global healthcare company Otsuka Pharmaceutical have formed a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist currently in development for the treatment of Alzheimer's disease.

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »

Recordati finalizes acquisition of portfolio from Lundbeck

Wednesday, January 23, 2013 11:25 AM

Recordati, a specialty pharmaceutical group based in Italy, has successfully concluded the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the U.S. from pharmaceutical company Lundbeck. The value of the transaction is of $100 million, of which $80 million were paid at the closing.

More... »

ImaginAb, Lundbeck to collaborate in neurodegeneration

Wednesday, October 10, 2012 12:49 PM

ImaginAb, an Inglewood, Calif.-based clinical-stage company developing in vivomolecular imaging agents, has entered into a collaboration and commercialization agreement with Lundbeck, an international pharmaceutical company, on a novel central nervous system (CNS) target in order to explore the use of re-engineered antibodies to accelerate the blood-brain barrier (BBB) transport of biologics.

More... »

Lundbeck files for EMA approval of vortioxetine for depression

Friday, September 21, 2012 01:34 PM

H. Lundbeck, an international pharmaceutical company, has submitted a marketing authorization application (MAA) to the EMA for the approval of the investigational multimodal antidepressant vortioxetine (Lu AA21004), and the dossier has been accepted for review.

More... »

Lundbeck, CHDI Foundation collaborate on Huntington’s disease

Tuesday, May 22, 2012 10:23 AM

Lundbeck, a pharmaceutical company based in Deerfield, Ill. and CHDI Foundation, a not-for-profit biomedical research organization, have formed a research collaboration to investigate a targeted therapy for Huntington’s disease.

More... »

The CenterWatch Monthly, April 2012

Sunday, April 1, 2012 06:30 AM

Global sites see growth in trials, revenue, staffing

More... »

Otsuka, H. Lundbeck partner to develop innovative medicines

Friday, November 11, 2011 11:02 AM

Otsuka Pharmaceutical and H. Lundbeck have entered into a long-term agreement for the development and commercialization of up to five innovative psychiatric and neuroscience products worldwide.

More... »

Lunudbeck to invest $16 million in Proximagen

Thursday, September 29, 2011 01:00 PM

Danish pharmaceutical group Lundbeck is to invest $6.1 million in British peer Proximagen Group as part of a strategic partnership, the companies said, according to Reuters.

More... »

Lundbeck Canada donates $2.7 million towards depression study

Tuesday, August 30, 2011 10:25 AM

The Canadian subsidiary of neurological disease specialist Lundbeck has donated $2.7 million towards a nationwide study aimed at identifying biomarkers of major depression and bipolar disorder, according to PharmaTimes.

More... »